# Verisk Analytics, Inc. – Consensus ‘buy’ rating and 4.0% Upside Potential

- Link: https://www.directorstalkinterviews.com/verisk-analytics-inc.consensus-buy-rating-and-4.0-upside-potential/4121134810
- Published: 2023-12-01T12:38:43+00:00
- Author: Charlotte Edwards

**Verisk Analytics, Inc.** with ticker code (VRSK) now have 16 analysts in total
covering the stock. The consensus rating is pointing to ‘buy’. The range between
the high target price and low target price is between $285.00 and $205.00 and has
a mean target at $247.88. Now with the previous closing price of $238.26 this would
imply there is now a potential upside of 4.0%. It’s also worth noting that there
is a 50 day moving average of $236.92 and the 200 day MA is $219.19. The company
has a market capitalization of 35.00B. The current share price for the company is:
$241.43 USD

 The potential market cap would be $36,417,543,324 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 45.21, revenue per share of $17.63
and a 8.07% return on assets.

Verisk Analytics, Inc. is a data analytics provider that serves insurance industry.
The Company offers predictive analytics and decision support solutions to customers
in rating, underwriting, claims, catastrophe and weather risk, global risk analytics,
and many other fields. The Company’s Insurance segment primarily serves its property
and casualty (P&C) insurance customers and focuses on the prediction of loss, the
selection and pricing of risk, and compliance with their reporting requirements 
in each United States state in which the Company operate. The Company also develop
and utilize machine learned and artificially intelligent models to forecast scenarios
and produce both standard and customized analytics that help its customers better
manage their businesses, including detecting fraud before and after a loss event
and quantifying losses. It also helps businesses and governments better anticipate
and manage climate and weather-related risks.

Share on: